The Hong Kong Hospital Authority reported that in the week prior to Sept. 25, it received 25 reports of adverse events following COVID-19 immunization, including a boy and a girl under 3 years old who experienced facial weakness, and one boy and one youth complaining of chest pains. (Sung Pi-Long/The Epoch Times)
For a valid vaccine pass in Hong Kong the requirement will be raised to three doses of vaccine starting Nov. 30, for ages 12 years upward
The Hong Kong government announced in its update on monitoring COVID-19 vaccination on Sept. 28, stating that in the past week till 11:59 p.m. on Sept. 25, the Hong Kong Department of Health (DH) had received a total of 25 reports of adverse events following COVID-19 immunization, including a 2-year-old boy and a 2-year-old girl, who experienced facial weakness after receiving Sinovac CoronaVac vaccines; a 9-year-old boy who received a CoronaVac vaccine and a 15-year-old youth who received Comirnaty mRNA Pfizer-BioNTech vaccine experienced chest pain and suspected myocarditis or pericarditis.
Meanwhile, the Center for Health Prevention (CHP) did not receive in the same one-week period any death reports involving individuals who had received COVID-19 vaccination within 14 days before death.
The DH has so far received 120 cases involving people who had received vaccination within 14 days before death.
The Expert Committee on Clinical Event Assessment Following COVID-19 Immunisation has so far concluded that 97 death cases had no causal relationship with vaccination, while for one case the causal relationship with vaccination could not be established, and preliminarily considered that 11 cases were not associated with vaccination. Eleven cases are still pending further information for assessment.
The spokesman also reminded that the vaccination requirements for persons aged 12 or above under the “Vaccine Pass” will be changed to requiring three doses of vaccine starting Nov. 30.